Humacyte Inc

Humacyte, Inc. develops and manufactures off-the-shelf, implantable, bioengineered human tissues for treating diseases across multiple therapeutic areas and anatomic locations. Using its proprietary technology platform, the company engineers human acellular vessels (HAVs) designed to be implanted without triggering a foreign body response or immune rejection. Its HAV portfolio targets vascular repair, reconstruction, and replacement markets, including vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, pediatric heart surgery, and coronary artery bypass grafting, as well as cellular therapy delivery such as pancreatic islet cell transplantation for Type 1 diabetes. Founded in 2004, Humacyte is headquartered in Durham, North Carolina.